- Home
- SXTP vs PRTG Comparison
SXTP vs PRTG Comparison
Compare SXTP & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- PRTG
- Stock Information
- Founded
- SXTP 2010
- PRTG 1973
- Country
- SXTP United States
- PRTG British Virgin Islands
- Employees
- SXTP N/A
- PRTG N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- PRTG Oil & Gas Production
- Sector
- SXTP Health Care
- PRTG Energy
- Exchange
- SXTP Nasdaq
- PRTG Nasdaq
- Market Cap
- SXTP 3.0M
- PRTG 3.2M
- IPO Year
- SXTP 2023
- PRTG N/A
- Fundamental
- Price
- SXTP $1.04
- PRTG $6.71
- Analyst Decision
- SXTP Buy
- PRTG Hold
- Analyst Count
- SXTP 2
- PRTG 1
- Target Price
- SXTP $28.80
- PRTG N/A
- AVG Volume (30 Days)
- SXTP 87.5K
- PRTG 119.1K
- Earning Date
- SXTP 11-18-2024
- PRTG 11-26-2024
- Dividend Yield
- SXTP N/A
- PRTG N/A
- EPS Growth
- SXTP N/A
- PRTG N/A
- EPS
- SXTP N/A
- PRTG N/A
- Revenue
- SXTP $441,255.00
- PRTG N/A
- Revenue This Year
- SXTP $267.05
- PRTG N/A
- Revenue Next Year
- SXTP $181.82
- PRTG N/A
- P/E Ratio
- SXTP N/A
- PRTG N/A
- Revenue Growth
- SXTP 12.07
- PRTG N/A
- 52 Week Low
- SXTP $0.92
- PRTG $2.10
- 52 Week High
- SXTP $18.36
- PRTG $47.00
- Technical
- Relative Strength Index (RSI)
- SXTP 39.03
- PRTG 53.44
- Support Level
- SXTP $0.92
- PRTG $6.12
- Resistance Level
- SXTP $1.38
- PRTG $7.45
- Average True Range (ATR)
- SXTP 0.11
- PRTG 0.86
- MACD
- SXTP 0.01
- PRTG -0.08
- Stochastic Oscillator
- SXTP 26.72
- PRTG 50.04
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.